Ear6 Inhibitors
Ear6, a gene predicted to enable ribonuclease activity, holds a crucial role in cellular processes, particularly in chemotaxis and innate immune responses within mucosal environments. Its predicted activity in the extracellular space underscores its significance in extracellular processes. Furthermore, the orthology to human RNASE2 and RNASE3, both members of the ribonuclease A family, suggests shared functional characteristics, highlighting the evolutionary conservation of this gene.
The potential inhibition of Ear6 involves a diverse array of mechanisms targeting specific cellular pathways. These mechanisms include the disruption of ribonuclease activity, modulation of chemotaxis pathways, and alterations in lysosomal function. For instance, inhibitors may target the MAPK pathway, affecting downstream cellular responses and indirectly impacting Ear6. Similarly, compounds can disrupt lysosomal acidification, influencing the subcellular localization of Ear6 and impairing its function. Chemotaxis pathways may be modulated to indirectly inhibit Ear6, altering its participation in directed cell movement. These varied approaches highlight the complexity of potential Ear6 inhibition, reflecting the intricate interplay of cellular processes in which it is involved. The understanding of these mechanisms provides insights into potential strategies for modulating Ear6's activity, contributing to a deeper understanding of its role in cellular and immune functions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
Inhibits Ear6 by targeting neutral sphingomyelinase (nSMase), disrupting sphingomyelin metabolism. This disrupts extracellular vesicle release and influences chemotaxis and mucosal immune responses by altering the composition of the extracellular space. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Acts as an indirect inhibitor by targeting p38 MAPK, modulating chemotaxis pathways associated with Ear6. This influences the gene's participation in chemotactic responses by affecting downstream signaling events in innate immune responses in mucosa. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Acts as an indirect inhibitor by targeting PI3K, modulating chemotaxis pathways associated with Ear6, and altering its participation in chemotactic responses. This impacts downstream signaling events and cellular processes related to mucosal immune responses. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits c-Jun N-terminal kinase (JNK), impacting innate immune responses in mucosa and indirectly suppressing Ear6 through immune-related signaling pathways. This influences the gene's participation in chemotactic responses by affecting downstream JNK-mediated events. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Disrupts lysosomal acidification, affecting the subcellular localization of Ear6 and impairing its function due to mislocalization within the cell. This alters the gene's participation in ribonuclease activity and chemotactic responses associated with the extracellular space. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits Ear6 indirectly by targeting PI3K, modulating chemotaxis pathways and influencing its participation in chemotactic responses. This impacts downstream signaling events and cellular processes related to mucosal immune responses, altering the gene's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Targets MEK1/2 within the MAPK/ERK pathway, indirectly inhibiting Ear6. This influences downstream cellular responses associated with ribonuclease activity and chemotaxis, altering the gene's participation in extracellular space and mucosal immune responses. | ||||||
JNK Inhibitor XVI | 1410880-22-6 | sc-364745 | 10 mg | $357.00 | 5 | |
Inhibits JNK, impacting innate immune responses in mucosa and suppressing Ear6 through immune-related signaling pathways. This influences the gene's participation in chemotactic responses by affecting downstream JNK-mediated events and cellular processes. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Affects lysosomal acidification, disrupting the subcellular localization of Ear6 and impairing its function. This alteration in localization influences the gene's participation in ribonuclease activity and chemotactic responses associated with the extracellular space. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Targets Src kinase, modulating chemotaxis pathways associated with Ear6, influencing its participation in chemotactic responses. This impacts downstream signaling events and cellular processes related to mucosal immune responses, altering the gene's function. | ||||||